pp-145 Solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: BCG-unresponsive NMIBC (FDA approved with BCG, 2024); Phase 3 expansion: NSCLC, colorectal, head and neck
Clinical stage: Approved (NMIBC) + Phase 3 solid tumour expansion
Modality: Biologic (IL-15/IL-15Rα-Fc fusion superagonist complex)
Mechanism / Target: IL-15 superagonist — activates NK cells and CD8+ memory T cells without Treg expansion; trans-presents IL-15 via IL-15Rα for superior potency vs IL-15 monomer
Route / form: Intravesical instillation (bladder); intravenous infusion (systemic tumours)
Differentiation: First-approved IL-15 agent; avoids Treg-stimulating IL-2 effects; broad combinability with checkpoint inhibitors; proven activity in bladder cancer with intravesical delivery
Manufacturer #39176
Commercial-stage immuno-oncology company with an FDA-approved IL-15 superagonist. Expands approved asset into multiple solid tumour indications with wholly owned Phase 3 studies. Integrated manufacturing and commercialisation infrastructure in oncology.
None